Congenital Myasthenic Syndrome research hub

A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

This study is testing a new medicine, ARGX-119, for adults with a specific type of muscle weakness called DOK7-Congenital Myasthenic Syndrome (CMS). It's looking at how safe the medicine is, if it causes side effects, and if it helps people feel better.